TNL Mediagene
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- TNL Mediagene Co., Ltd. is a biotechnology company primarily engaged in the development, manufacture, and sale of medical diagnostic products and related services. The company's core product portfolio includes molecular diagnostic reagents, in vitro diagnostic kits, nucleic acid extraction reagents, and medical testing devices. TNL Mediagene develops and provides advanced genetic testing products and services focusing on clinical diagnostics, including infectious diseases, oncology, and genetic disorders. Its offerings encompass DNA/RNA extraction kits, PCR reagents, and gene expression analysis tools that support medical institutions, research laboratories, and pharmaceutical companies. The company operates primarily in South Korea while serving international markets through strategic partnerships and distribution channels. Founded in 1997, TNL Mediagene is headquartered in Seoul, South Korea. It has continued to expand its research and development capabilities and product offerings in the molecular diagnostics industry segment. Recent major company developments include strategic alliances with global biotech firms to co-develop novel diagnostic solutions and recent product launches addressing emerging healthcare needs. In the past 1-2 years, TNL Mediagene has strengthened its position in precision medicine diagnostics by expanding its portfolio into next-generation sequencing (NGS) technologies and integrated diagnostic platforms. The company also enhanced its operational footprint by investing in manufacturing and R&D infrastructure to support advanced genomics and personalized medicine markets. TNL Mediagene's business segmentation includes molecular diagnostics reagents and medical device manufacturing, targeting healthcare providers, clinical laboratories, and research institutions. As an innovator in genetic testing and molecular pathology, the company plays a significant role in South Korea's biotech and medical diagnostics industry. Its comprehensive suite of diagnostic products and technology solutions underpins clinical decision-making and therapeutic strategies worldwide. The company continues to focus on innovation, strategic partnerships, and geographic expansion to maintain its competitive position and support the evolving global demand for molecular diagnostic products and services.
Company News
TNL Mediagene Announces 1-for-8 Share Consolidation
TNL Mediagene Granted Continued Nasdaq Listing Subject to Conditions
TNL Mediagene's Infobahn Begins Delivering Enterprise Organizational Design Services Built on Miro's AI-Powered Workspace
TNL Mediagene and Totaligent Take Different Paths Toward the Future of Enterprise Marketing
TNL Mediagene and Miro Bring AI-Powered Organizational Design Services to Enterprise Clients in Japan
TNL Mediagene Establishes Special Committee to Evaluate Strategic Alternatives, Engages Imperial Capital as Financial Advisor to Pursue Strategic Alternatives to Maximize Shareholder Value
TNL Mediagene Completes Full Repayment of Senior Convertible Note and Mutually Terminates Note Purchase Agreement with 3i, LP
"Keychron Orca echo" by Keychron x GIZMART Becomes First GIZMART Project to Surpass JPY 500 Million in GMV
TNL Mediagene Selected as One of 8 Taiwan Media Organizations for FT Strategies AI Lab, Supported by the Google News Initiative
"Keychron Orca echo" by Keychron x GIZMART Tops JPY 300 Million GMV in 5 Days, Setting a New GIZMART Crowdfunding Record
TNL Mediagene Receives Nasdaq Delisting Determination and Plans to Request Hearing
TNL Mediagene's Business Insider Taiwan Tops One Million Monthly Views in First Year, Surpassing 50,000 Subscribers on its YouTube Channel
TNL Mediagene's GIZMART Expands Co-Development Partnership with Keychron and Kopek Japan, Launching Keychron T1 HE Pre-Sale in Japan
Ad2iction, a TNL Mediagene Subsidiary, Launches Upgraded Ad2 AI Audience Integrating Retail Transaction and Intent Signals
TNL Mediagene Announces Receipt of Deficiency Letter from Nasdaq
TNL Mediagene Files FY2025 Annual Report on Form 20-F; Reports Continued Digital Studio Leadership and Significant Year-over-Year Net Loss Reduction
TNL Mediagene Delivers $4M Digital Studio Project with AI, Cutting Review Costs by Over 98%
TNL Mediagene Announces Leadership Realignment and 2026 Strategic Initiatives to Strengthen Execution, Expand Digital Studio, Content Commerce and AI-Powered Products, and Drive Long-Term Value Creation
TNL Mediagene Announces Exclusive Partnership with Moby to Launch "Moby Japan" on Business Insider Japan Platform
TNL Mediagene (NASDAQ:TNMG) Sees Significant Decrease in Short Interest